Rachel Marie DeVay JACOBSON,Hong LIANG,David Shelton
申请号：
US15501752
公开号：
US20170224816A1
申请日:
2015.07.29
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to methods for the treatment of reducing LDL-cholesterol levels in a subject infected with hepatitis C virus (HCV) or at high risk of contracting HCV comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human PCSK9 protein. The subject treatment can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including hypercholesterolemia, dyslipidemia, hyperlipidemia, atherosclerosis, acute coronary syndrome and, more generally, cardiovascular disease (CVD).
